Background: In human tissues, alkaline phosphatase (ALP) is a membrane-bound glycoprotein with the highest activity reported in kidneys, bone as well as in liver. In recent years, it has emerged as a risk factor for cardiovascular disease. ALP has been linked to increased vascular inflammation as well as calcification in both laboratory and clinical trials. Blood ALP activity has been associated with an increased risk of death or significant adverse cardiovascular events such as stroke, myocardial infarction, coronary revascularization, coronary slow flow phenomenon, and peripheral artery disease in epidemiological studies. Patients with chronic renal disease may benefit from medication therapy aimed at improving bone AP, according to new research. Objective: This review article aimed to evaluate the Potential relationship between cardiovascular disease and alkaline phosphatase. Methods: The databases were searched for articles published in English in 3 data bases [PubMed, Google scholar and science direct] and Boolean operators (AND, OR, NOT) had been used such as [alkaline phosphatase  AND cardiovascular disease OR CVD]  and in peer-reviewed articles between June 2005 and October 2021. Conclusion: Diagnosis of cardiovascular disease (CVD) is not based on ALP measurement. According to recent research, heart disease and CVD-related death are both more likely in people with higher levels of AP activity.